推荐产品
product name
(±)-Blebbistatin, (±)-Blebbistatin, CAS 674289-55-5, is a cell-permeable, selective, and reversible inhibitor of nonmuscle myosin II. Blocks cell blebbing and disrupts cell migration & cytoKinesis in vertebrate cells.
品質等級
化驗
≥97% (HPLC)
形狀
solid
製造商／商標名
Calbiochem®
儲存條件
OK to freeze
protect from light
顏色
yellow
溶解度
methanol: 1.5 mg/mL
100% DMSO: 100 mg/mL
90% DMSO: 75 mg/mL
運輸包裝
wet ice
儲存溫度
−20°C
InChI
1S/C18H16N2O2/c1-12-7-8-15-14(11-12)16(21)18(22)9-10-20(17(18)19-15)13-5-3-2-4-6-13/h2-8,11,22H,9-10H2,1H3
InChI 密鑰
LZAXPYOBKSJSEX-UHFFFAOYSA-N
一般說明
一种可渗透细胞的化合物，作为非肌肉肌球蛋白Ⅱ的选择性、强效和可逆抑制剂。抑制人血小板（≤100 µM）的ATP酶和滑动运动，而不影响肌球蛋白轻链激酶（MLCK）的活性。已经显示出可以阻止细胞起泡并迅速破坏脊椎动物细胞中的定向细胞迁移和胞质分裂。不会破坏有丝分裂或影响收缩环的组装。
一种可渗透细胞的化合物，作为非肌肉肌球蛋白Ⅱ的选择性、强效和可逆抑制剂。抑制人血小板（≤100 µM）的ATP酶和滑动运动，而不影响肌球蛋白轻链激酶（MLCK）的活性。已经显示出可以阻止细胞起泡并迅速破坏脊椎动物细胞中的定向细胞迁移和胞质分裂。不会破坏有丝分裂或影响收缩环的组装。也可使用50 mM（5 mg/342 µl）（±）-Blebbistatin在90% DMSO的溶液（目录号203389）。
生化／生理作用
主要靶标
ATPase
ATPase
产物不与ATP竞争。
可逆性：是
细胞可渗透性：是
靶标IC50：<100 µM 抑制人血小板的ATP酶和滑动运动
包裝
用惰性气体包装
重構
在90% DMSO中复溶后，等分并冷冻保存（-20°C）。90% DMSO中的储备液可在-20°C下稳定保存1个月。100%DMSO中的储备溶液不稳定；临用前复溶。
其他說明
Shu, S., et al. 2005.Proc.Natl.Acad.Sci. USA102, 1472.
Kovacs, M., et al. 2004.J. Biol. Chem.279, 35557.
Straight, A.F., et al. 2003.Science299, 1743.
Cheung, A., et al. 2001.Mol.Biol. Cell Suppl.12, 271a.
Kovacs, M., et al. 2004.J. Biol. Chem.279, 35557.
Straight, A.F., et al. 2003.Science299, 1743.
Cheung, A., et al. 2001.Mol.Biol. Cell Suppl.12, 271a.
法律資訊
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Ling-Yea Yu et al.
Bio-protocol, 13(21), e4867-e4867 (2023-11-16)
Cell signaling is highly integrated for the process of various cell activities. Although previous studies have shown how individual genes contribute to cell migration, it remains unclear how the integration of these signaling pathways is involved in the modulation of
Sarah Escuin et al.
Disease models & mechanisms, 16(3) (2023-03-15)
Understanding the molecular mechanisms that lead to birth defects is an important step towards improved primary prevention. Mouse embryos homozygous for the Kumba (Ku) mutant allele of Zic2 develop severe spina bifida with complete lack of dorsolateral hinge points (DLHPs)
Mark Sweeney et al.
International journal of molecular sciences, 24(16) (2023-08-26)
Cardiac fibrosis is a common pathological process in heart disease, representing a therapeutic target. Transforming growth factor β (TGFβ) is the canonical driver of cardiac fibrosis and was recently shown to be dependent on interleukin 11 (IL11) for its profibrotic
Antonios Georgantzoglou et al.
The Journal of cell biology, 221(8) (2022-06-23)
Migrating cells must interpret chemical gradients to guide themselves within tissues. A long-held principle is that gradients guide cells via reorientation of leading-edge protrusions. However, recent evidence indicates that protrusions can be dispensable for locomotion in some contexts, raising questions
Nathan J VanDusen et al.
Nature communications, 12(1), 4442-4442 (2021-07-23)
The forward genetic screen is a powerful, unbiased method to gain insights into biological processes, yet this approach has infrequently been used in vivo in mammals because of high resource demands. Here, we use in vivo somatic Cas9 mutagenesis to
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门